

Global Primary Sclerosing Cholangitis (PSC) Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/GE5DCDE14135EN.html>

Date: May 2026

Pages: 138

Price: US\$ 3,660.00 (Single User License)

ID: GE5DCDE14135EN

Abstracts

The global Primary Sclerosing Cholangitis (PSC) market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that primarily affects the bile ducts. The term 'sclerosing' refers to the scarring and narrowing (stricturing) of the bile ducts, which impedes the flow of bile from the liver to the small intestine. PSC is characterized by inflammation and fibrosis of the bile ducts, leading to a range of liver and digestive issues.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US\$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents' wealth and the improvement of health awareness will drive the demand for medicines.

LPI (LP Information)' newest research report, the "Primary Sclerosing Cholangitis (PSC) Industry Forecast" looks at past sales and reviews total world Primary Sclerosing Cholangitis (PSC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Primary Sclerosing Cholangitis (PSC) sales for 2026 through 2032. With Primary Sclerosing Cholangitis (PSC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Primary Sclerosing Cholangitis (PSC) industry.

This Insight Report provides a comprehensive analysis of the global Primary Sclerosing Cholangitis (PSC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Primary Sclerosing Cholangitis (PSC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Primary Sclerosing Cholangitis (PSC) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Sclerosing Cholangitis (PSC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Sclerosing Cholangitis (PSC).

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Sclerosing Cholangitis (PSC) market by product type, application, key players and key regions and countries.

Segmentation by Type:

Medical Treatment

Liver Transplantation

Others

Segmentation by Application:

Hospital

Clinics

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Acorda Therapeutics

Gilead Sciences

NGM Biopharmaceuticals

Intercept Pharmaceuticals

Dr. Falk Pharma

Allergan

Shire

Durect Corporation

Conatus Pharmaceuticals

Sirnaomics

Shenzhen HighTide Biopharmaceutical

Glenmark

Impax Laboratories

Mylan

Teva Pharmaceuticals

Daewoong Pharmaceutical

Mitsubishi Tanabe Pharma

Lannett

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Primary Sclerosing Cholangitis (PSC) Market Size (2021-2032)
- 2.1.2 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region (2021 VS 2025 VS 2032)
- 2.1.3 World Current & Future Analysis for Primary Sclerosing Cholangitis (PSC) by Country/Region (2021, 2025 & 2032)

2.2 Primary Sclerosing Cholangitis (PSC) Segment by Type

- 2.2.1 Medical Treatment
- 2.2.2 Liver Transplantation
- 2.2.3 Others
- 2.2.4 Primary Sclerosing Cholangitis (PSC) Market Size by Type
 - 2.2.4.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.4.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)

2.3 Primary Sclerosing Cholangitis (PSC) Segment by Application

- 2.3.1 Hospital
- 2.3.2 Clinics
- 2.3.3 Others
- 2.3.4 Primary Sclerosing Cholangitis (PSC) Market Size by Application
 - 2.3.4.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2021 VS 2025 VS 2032)
 - 2.3.4.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)

3 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SIZE BY PLAYER

3.1 Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Player

3.1.1 Global Primary Sclerosing Cholangitis (PSC) Revenue by Player (2021-2026)

3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player (2021-2026)

3.2 Global Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 PRIMARY SCLEROSING CHOLANGITIS (PSC) BY REGION

4.1 Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026)

4.2 Global Primary Sclerosing Cholangitis (PSC) Annual Revenue by Country/Region (2021-2026)

4.3 Americas Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)

4.4 APAC Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)

4.5 Europe Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)

4.6 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026)

5.2 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)

5.3 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026)

6.2 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)

6.3 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026)

7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)

7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) by Region (2021-2026)

8.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type
(2021-2026)

8.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by
Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET FORECAST

- 10.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
 - 10.1.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
 - 10.1.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.1.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.1.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.1.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast
- 10.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast by Country (2027-2032)
 - 10.2.1 United States Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.2.2 Canada Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.2.3 Mexico Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.2.4 Brazil Market Primary Sclerosing Cholangitis (PSC) Forecast
- 10.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
 - 10.3.1 China Primary Sclerosing Cholangitis (PSC) Market Forecast
 - 10.3.2 Japan Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.3.3 Korea Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.3.4 Southeast Asia Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.3.5 India Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.3.6 Australia Market Primary Sclerosing Cholangitis (PSC) Forecast
- 10.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast by Country (2027-2032)
 - 10.4.1 Germany Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.4.2 France Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.4.3 UK Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.4.4 Italy Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.4.5 Russia Market Primary Sclerosing Cholangitis (PSC) Forecast
- 10.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.5.2 South Africa Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.5.3 Israel Market Primary Sclerosing Cholangitis (PSC) Forecast
 - 10.5.4 Turkey Market Primary Sclerosing Cholangitis (PSC) Forecast
- 10.6 Global Primary Sclerosing Cholangitis (PSC) Forecast by Type (2027-2032)
- 10.7 Global Primary Sclerosing Cholangitis (PSC) Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Primary Sclerosing Cholangitis (PSC) Forecast

11 KEY PLAYERS ANALYSIS

11.1 Acorda Therapeutics

11.1.1 Acorda Therapeutics Company Information

11.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered

11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)

11.1.4 Acorda Therapeutics Main Business Overview

11.1.5 Acorda Therapeutics Latest Developments

11.2 Gilead Sciences

11.2.1 Gilead Sciences Company Information

11.2.2 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered

11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)

11.2.4 Gilead Sciences Main Business Overview

11.2.5 Gilead Sciences Latest Developments

11.3 NGM Biopharmaceuticals

11.3.1 NGM Biopharmaceuticals Company Information

11.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered

11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 NGM Biopharmaceuticals Main Business Overview

11.3.5 NGM Biopharmaceuticals Latest Developments

11.4 Intercept Pharmaceuticals

11.4.1 Intercept Pharmaceuticals Company Information

11.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered

11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 Intercept Pharmaceuticals Main Business Overview

11.4.5 Intercept Pharmaceuticals Latest Developments

11.5 Dr. Falk Pharma

11.5.1 Dr. Falk Pharma Company Information

11.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered

11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 Dr. Falk Pharma Main Business Overview

- 11.5.5 Dr. Falk Pharma Latest Developments
- 11.6 Allergan
 - 11.6.1 Allergan Company Information
 - 11.6.2 Allergan Primary Sclerosing Cholangitis (PSC) Product Offered
 - 11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Allergan Main Business Overview
 - 11.6.5 Allergan Latest Developments
- 11.7 Shire
 - 11.7.1 Shire Company Information
 - 11.7.2 Shire Primary Sclerosing Cholangitis (PSC) Product Offered
 - 11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 Shire Main Business Overview
 - 11.7.5 Shire Latest Developments
- 11.8 Durect Corporation
 - 11.8.1 Durect Corporation Company Information
 - 11.8.2 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered
 - 11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Durect Corporation Main Business Overview
 - 11.8.5 Durect Corporation Latest Developments
- 11.9 Conatus Pharmaceuticals
 - 11.9.1 Conatus Pharmaceuticals Company Information
 - 11.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
 - 11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Conatus Pharmaceuticals Main Business Overview
 - 11.9.5 Conatus Pharmaceuticals Latest Developments
- 11.10 Sirnaomics
 - 11.10.1 Sirnaomics Company Information
 - 11.10.2 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered
 - 11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 Sirnaomics Main Business Overview
 - 11.10.5 Sirnaomics Latest Developments
- 11.11 Shenzhen HighTide Biopharmaceutical
 - 11.11.1 Shenzhen HighTide Biopharmaceutical Company Information

11.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC)
Product Offered

11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC)
Revenue, Gross Margin and Market Share (2021-2026)

11.11.4 Shenzhen HighTide Biopharmaceutical Main Business Overview

11.11.5 Shenzhen HighTide Biopharmaceutical Latest Developments

11.12 Glenmark

11.12.1 Glenmark Company Information

11.12.2 Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered

11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and
Market Share (2021-2026)

11.12.4 Glenmark Main Business Overview

11.12.5 Glenmark Latest Developments

11.13 Impax Laboratories

11.13.1 Impax Laboratories Company Information

11.13.2 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered

11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue, Gross
Margin and Market Share (2021-2026)

11.13.4 Impax Laboratories Main Business Overview

11.13.5 Impax Laboratories Latest Developments

11.14 Mylan

11.14.1 Mylan Company Information

11.14.2 Mylan Primary Sclerosing Cholangitis (PSC) Product Offered

11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and
Market Share (2021-2026)

11.14.4 Mylan Main Business Overview

11.14.5 Mylan Latest Developments

11.15 Teva Pharmaceuticals

11.15.1 Teva Pharmaceuticals Company Information

11.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered

11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross
Margin and Market Share (2021-2026)

11.15.4 Teva Pharmaceuticals Main Business Overview

11.15.5 Teva Pharmaceuticals Latest Developments

11.16 Daewoong Pharmaceutical

11.16.1 Daewoong Pharmaceutical Company Information

11.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product
Offered

11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue,

Gross Margin and Market Share (2021-2026)

11.16.4 Daewoong Pharmaceutical Main Business Overview

11.16.5 Daewoong Pharmaceutical Latest Developments

11.17 Mitsubishi Tanabe Pharma

11.17.1 Mitsubishi Tanabe Pharma Company Information

11.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered

11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)

11.17.4 Mitsubishi Tanabe Pharma Main Business Overview

11.17.5 Mitsubishi Tanabe Pharma Latest Developments

11.18 Lannett

11.18.1 Lannett Company Information

11.18.2 Lannett Primary Sclerosing Cholangitis (PSC) Product Offered

11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)

11.18.4 Lannett Main Business Overview

11.18.5 Lannett Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)
- Table 2. Primary Sclerosing Cholangitis (PSC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Medical Treatment
- Table 4. Major Players of Liver Transplantation
- Table 5. Major Players of Others
- Table 6. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)
- Table 7. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & (\$ millions)
- Table 8. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
- Table 9. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)
- Table 10. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & (\$ millions)
- Table 11. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
- Table 12. Global Primary Sclerosing Cholangitis (PSC) Revenue by Player (2021-2026) & (\$ millions)
- Table 13. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player (2021-2026)
- Table 14. Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered
- Table 15. Primary Sclerosing Cholangitis (PSC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- Table 16. New Products and Potential Entrants
- Table 17. Mergers & Acquisitions, Expansion
- Table 18. Global Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & (\$ millions)
- Table 19. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
- Table 20. Global Primary Sclerosing Cholangitis (PSC) Revenue by Country/Region (2021-2026) & (\$ millions)

Table 21. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Country/Region (2021-2026)

Table 22. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026) & (\$ millions)

Table 23. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2021-2026)

Table 24. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & (\$ millions)

Table 25. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)

Table 26. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & (\$ millions)

Table 27. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)

Table 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & (\$ millions)

Table 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)

Table 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & (\$ millions)

Table 31. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & (\$ millions)

Table 32. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026) & (\$ millions)

Table 33. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2021-2026)

Table 34. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & (\$ millions)

Table 35. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & (\$ millions)

Table 36. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & (\$ millions)

Table 38. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & (\$ millions)

Table 39. Key Market Drivers & Growth Opportunities of Primary Sclerosing Cholangitis (PSC)

Table 40. Key Market Challenges & Risks of Primary Sclerosing Cholangitis (PSC)

- Table 41. Key Industry Trends of Primary Sclerosing Cholangitis (PSC)
- Table 42. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region (2027-2032) & (\$ millions)
- Table 43. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Region (2027-2032)
- Table 44. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2027-2032) & (\$ millions)
- Table 45. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Application (2027-2032) & (\$ millions)
- Table 46. Acorda Therapeutics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
- Table 47. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered
- Table 48. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 49. Acorda Therapeutics Main Business
- Table 50. Acorda Therapeutics Latest Developments
- Table 51. Gilead Sciences Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
- Table 52. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered
- Table 53. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 54. Gilead Sciences Main Business
- Table 55. Gilead Sciences Latest Developments
- Table 56. NGM Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
- Table 57. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
- Table 58. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 59. NGM Biopharmaceuticals Main Business
- Table 60. NGM Biopharmaceuticals Latest Developments
- Table 61. Intercept Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
- Table 62. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
- Table 63. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 64. Intercept Pharmaceuticals Main Business
- Table 65. Intercept Pharmaceuticals Latest Developments

Table 66. Dr. Falk Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 67. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered

Table 68. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 69. Dr. Falk Pharma Main Business

Table 70. Dr. Falk Pharma Latest Developments

Table 71. Allergan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 72. Allergan Primary Sclerosing Cholangitis (PSC) Product Offered

Table 73. Allergan Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 74. Allergan Main Business

Table 75. Allergan Latest Developments

Table 76. Shire Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 77. Shire Primary Sclerosing Cholangitis (PSC) Product Offered

Table 78. Shire Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 79. Shire Main Business

Table 80. Shire Latest Developments

Table 81. Durect Corporation Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 82. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered

Table 83. Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 84. Durect Corporation Main Business

Table 85. Durect Corporation Latest Developments

Table 86. Conatus Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 87. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered

Table 88. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 89. Conatus Pharmaceuticals Main Business

Table 90. Conatus Pharmaceuticals Latest Developments

Table 91. Sirnaomics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 92. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered

Table 93. Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 94. Sirnaomics Main Business

Table 95. Sirnaomics Latest Developments

Table 96. Shenzhen HighTide Biopharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 97. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered

Table 98. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 99. Shenzhen HighTide Biopharmaceutical Main Business

Table 100. Shenzhen HighTide Biopharmaceutical Latest Developments

Table 101. Glenmark Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 102. Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered

Table 103. Glenmark Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 104. Glenmark Main Business

Table 105. Glenmark Latest Developments

Table 106. Impax Laboratories Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 107. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered

Table 108. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 109. Impax Laboratories Main Business

Table 110. Impax Laboratories Latest Developments

Table 111. Mylan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 112. Mylan Primary Sclerosing Cholangitis (PSC) Product Offered

Table 113. Mylan Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 114. Mylan Main Business

Table 115. Mylan Latest Developments

Table 116. Teva Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 117. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered

Table 118. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 119. Teva Pharmaceuticals Main Business

Table 120. Teva Pharmaceuticals Latest Developments

Table 121. Daewoong Pharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 122. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered

Table 123. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 124. Daewoong Pharmaceutical Main Business

Table 125. Daewoong Pharmaceutical Latest Developments

Table 126. Mitsubishi Tanabe Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 127. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered

Table 128. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 129. Mitsubishi Tanabe Pharma Main Business

Table 130. Mitsubishi Tanabe Pharma Latest Developments

Table 131. Lannett Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors

Table 132. Lannett Primary Sclerosing Cholangitis (PSC) Product Offered

Table 133. Lannett Primary Sclerosing Cholangitis (PSC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 134. Lannett Main Business

Table 135. Lannett Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Primary Sclerosing Cholangitis (PSC) Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Primary Sclerosing Cholangitis (PSC) Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2025)

Figure 8. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type in 2025

Figure 10. Primary Sclerosing Cholangitis (PSC) in Hospital

Figure 11. Global Primary Sclerosing Cholangitis (PSC) Market: Hospital (2021-2026) & (\$ millions)

Figure 12. Primary Sclerosing Cholangitis (PSC) in Clinics

Figure 13. Global Primary Sclerosing Cholangitis (PSC) Market: Clinics (2021-2026) & (\$ millions)

Figure 14. Primary Sclerosing Cholangitis (PSC) in Others

Figure 15. Global Primary Sclerosing Cholangitis (PSC) Market: Others (2021-2026) & (\$ millions)

Figure 16. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application in 2025

Figure 17. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player in 2025

Figure 18. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)

Figure 19. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 (\$ millions)

Figure 20. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 (\$ millions)

Figure 21. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 (\$ millions)

Figure 23. Americas Primary Sclerosing Cholangitis (PSC) Value Market Share by Country in 2025

Figure 24. United States Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region in 2025

Figure 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)

Figure 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)

Figure 31. China Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country in 2025

Figure 38. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)

Figure 39. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)

Figure 40. Germany Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026

(\$ millions)

Figure 42. UK Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 54. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 55. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 57. United States Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 58. Canada Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 61. China Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 62. Japan Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 63. Korea Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 65. India Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 66. Australia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 67. Germany Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 68. France Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 69. UK Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 70. Italy Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 71. Russia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 74. Israel Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

Figure 76. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Primary Sclerosing Cholangitis (PSC) Market Growth (Status and Outlook)
2026-2032

Product link: <https://marketpublishers.com/r/GE5DCDE14135EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/GE5DCDE14135EN.html>